Clinical Benefits
SEPRAFILM® is proven to reduce post-operative adhesions and related complications. It has been studied in more than 4,000 patients and in 20 published clinical reports.1
Reduction in Reoperative Adhesive Small Bowel Obstruction
In a prospective, randomized, controlled, blinded, multicenter study of patients receiving SEPRAFILM during intestinal resection, SEPRAFILM reduced reoperation required for adhesive SBO by 47% relative to untreated controls.2
Reduction in Reoperative Complexity
In a series of prospective clinical studies in which SEPRAFILM was placed at the initial procedure, SEPRAFILM reduced adhesions observed at subsequent surgery, resulting in:
- Fewer inadvertent injuries3
- Less operative time4
- Reduced blood loss4
- Easier ileostomy reversal3
Reduction in Adhesions and Complexity at Repeat C-Section
In a study of patients receiving SEPRAFILM at primary C-section, SEPRAFILM significantly reduced adhesions, resulting in decreased procedure and delivery times at repeat C-section.4
